Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome

References

1. 1.↵
   2. Confavreux C,
   3. Vukusic S

   . Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606–16

   Abstract/FREE Full Text
2. 2.↵
   2. Zivadinov R,
   3. Bakshi R

   . Role of MRI in multiple sclerosis II: brain and spinal cord atrophy. Front Biosci 2004;9:647–64

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Miller DH,
   3. Barkhof F,
   4. Frank JA, et al

   . Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676–95

   Abstract/FREE Full Text
4. 4.↵
   2. Geurts JJ,
   3. Stys PK,
   4. Minagar A, et al

   . Gray matter pathology in (chronic) MS: modern views on an early observation. J Neurol Sci 2009;282:12–20

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Zivadinov R,
   3. Havrdová E,
   4. Bergsland N, et al

   . Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013;268:831–41

   CrossRefPubMed
6. 6.↵
   2. Calabrese M,
   3. Rinaldi F,
   4. Mattisi I, et al

   . The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011;77:257–63

   CrossRefPubMed
7. 7.↵
   2. Dalton CM,
   3. Chard DT,
   4. Davies GR, et al

   . Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127:1101–07

   Abstract/FREE Full Text
8. 8.↵
   2. Raz E,
   3. Cercignani M,
   4. Sbardella E, et al

   . Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. Radiology 2010;257:448–54

   CrossRefPubMedWeb of Science
9. 9.↵
   2. Fisniku LK,
   3. Chard DT,
   4. Jackson JS, et al

   . Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008;64:247–54

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Zivadinov R,
    3. Bergsland N,
    4. Dolezal O, et al

    . Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. AJNR Am J Neuroradiol 2013;34:1931–39

    Abstract/FREE Full Text
11. 11.↵
    2. Fisher E,
    3. Lee JC,
    4. Nakamura K, et al

    . Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255–65

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Cappellani R,
    3. Bergsland N,
    4. Weinstock-Guttman B, et al

    . Subcortical deep gray matter pathology in patients with multiple sclerosis is associated with white matter lesion burden and atrophy but not with cortical atrophy: a diffusion tensor MRI study. AJNR Am J Neuroradiol 2014;35:912–19

    Abstract/FREE Full Text
13. 13.↵
    2. Roosendaal SD,
    3. Bendfeldt K,
    4. Vrenken H, et al

    . Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler 2011;17:1098–106

    Abstract/FREE Full Text
14. 14.↵
    2. Kalincik T,
    3. Vaneckova M,
    4. Tyblova M, et al

    . Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLoS ONE 2012;7:e50101

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Uher T,
    3. Benedict RH,
    4. Horakova D, et al

    . Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. J Neurol Sci 2014;347:229–34

    CrossRefPubMed
16. 16.↵
    2. Uher T,
    3. Blahova-Dusankova J,
    4. Horakova D, et al

    . Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. J Neurol 2014;261:1735–44

    CrossRefPubMed
17. 17.↵
    2. Uher T,
    3. Horakova D,
    4. Bergsland N, et al

    . MRI correlates of disability progression in patients with CIS over 48 months. Neuroimage Clin 2014;6:312–19

    CrossRefPubMed
18. 18.↵
    2. Zivadinov R,
    3. Heininen-Brown M,
    4. Schirda CV, et al

    . Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 2012;59:331–39

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Smith SM,
    3. Zhang Y,
    4. Jenkinson M, et al

    . Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479–89

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Patenaude B,
    3. Smith SM,
    4. Kennedy DN, et al

    . A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011;56:907–22

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Smith SM,
    3. De Stefano N,
    4. Jenkinson M, et al

    . Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001;25:466–75

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Dwyer MG,
    3. Bergsland N,
    4. Zivadinov R

    . Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model. Neuroimage 2014;90:207–17

    CrossRefPubMed
23. 23.↵
    2. Benjamini Y,
    3. Drai D,
    4. Elmer G, et al

    . Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279–84

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Calabrese M,
    3. Atzori M,
    4. Bernardi V, et al

    . Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007;254:1212–20

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Comi G,
    3. Martinelli V,
    4. Rodegher M, et al

    . Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2013;19:1074–83

    Abstract/FREE Full Text
26. 26.↵
    2. Zivadinov R,
    3. Zorzon M

    . Is gadolinium enhancement predictive of the development of brain atrophy in multiple sclerosis? A review of the literature. J Neuroimaging 2002;12:302–09

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Zivadinov R,
    3. Bagnato F,
    4. Nasuelli D, et al

    . Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. J Neurol Sci 2004;223:185–93

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Rashid W,
    3. Davies GR,
    4. Chard DT, et al

    . Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study. Mult Scler 2007;13:178–85

    Abstract/FREE Full Text
29. 29.↵
    2. Inglese M,
    3. Mancardi GL,
    4. Pagani E, et al

    . Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry 2004;75:643–44

    Abstract/FREE Full Text
30. 30.↵
    2. Paolillo A,
    3. Piattella MC,
    4. Pantano P, et al

    . The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol 2004;251:432–39

    CrossRefPubMedWeb of Science
31. 31.↵
    2. De Stefano N,
    3. Giorgio A,
    4. Battaglini M, et al

    . Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010;74:1868–76

    CrossRefPubMed
32. 32.↵
    2. Rojas JI,
    3. Patrucco L,
    4. Míguez J, et al

    . Brain atrophy in radiologically isolated syndromes. J Neuroimaging 2015;25:68–71

    CrossRefPubMed
33. 33.↵
    2. Dalton CM,
    3. Brex PA,
    4. Jenkins R, et al

    . Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:141–47

    Abstract/FREE Full Text
34. 34.↵
    2. Magnano C,
    3. Schirda C,
    4. Weinstock-Guttman B, et al

    . Cine cerebrospinal fluid imaging in multiple sclerosis. J Magn Reson Imaging 2012;36:825–34

    CrossRefPubMed
35. 35.↵
    2. Lucchinetti CF,
    3. Popescu BF,
    4. Bunyan RF, et al

    . Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365:2188–97

    CrossRefPubMedWeb of Science
36. 36.↵
    2. Calabrese M,
    3. Rocca MA,
    4. Atzori M, et al

    . Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology 2009;72:1330–36

    CrossRefPubMed
37. 37.↵
    2. Bø L,
    3. Vedeler CA,
    4. Nyland H, et al

    . Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003;9:323–31

    Abstract/FREE Full Text
38. 38.↵
    2. van Horssen J,
    3. Brink BP,
    4. de Vries HE, et al

    . The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol 2007;66:321–28

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Geurts JJ,
    3. Pouwels PJ,
    4. Uitdehaag BM, et al

    . Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005;236:254–60

    CrossRefPubMedWeb of Science
40. 40.↵
    2. Fox RJ,
    3. Fisher E,
    4. Tkach J, et al

    . Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications. Mult Scler 2005;11:140–45

    Abstract/FREE Full Text
41. 41.↵
    2. Hardmeier M,
    3. Wagenpfeil S,
    4. Freitag P, et al

    . Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005;64:236–40

    CrossRefPubMed
42. 42.↵
    2. Vidal-Jordana A,
    3. Sastre-Garriga J,
    4. Pérez-Miralles F, et al

    . Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 2013;19:1175–81

    Abstract/FREE Full Text
43. 43.↵
    2. Zivadinov R,
    3. Reder AT,
    4. Filippi M, et al

    . Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71:136–44

    CrossRefPubMed